The Cell-Based Immunotherapy Market is expected to register a CAGR of 15.5% during the forecast period. Cellular immunotherapy also known as adoptive cell therapy is a form of treatment that uses the cells of the immune system to treat cancer.
The immune system is capable of recognizing and eliminating cells that are infected or damaged or cancerous. Immune cells known as killer T cells act against cancerous cells, due to their ability to bind to markers known as antigens on the surface of cancer cells. Cellular immunotherapies utilize the natural ability of the killer T cells and make them fight against cancer cells. Sometimes these T cells get activated before they can effectively kill cancer cells and might not exist in enough numbers to act against cancer cells. In order to address these issues, tumor-infiltrating lymphocyte (TIL) is one form of cell-based immunotherapy. CAR T-cell therapy is another form of cell-based immunotherapy that involves re-engineering a patient’s own T-cells to recognize and fight against cancer and these T-cells are genetically altered to express artificial receptors which enable the T-cells to bind to a specific antigen on the patient’s tumor cells and kill them.
In the year 2018 World Health Organization (WHO) estimated 18.1 million new cases of cancer and approximately 9.6 million deaths worldwide. In addition, one in 5 men and one in 6 women globally develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. Rising prevalence of cancer, technological advancement, and the development of novel target-based anti-cancer therapies are the key driving factors in the cell-based immunotherapy market.
Key Market Trends
Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment is Expected to Hold a Major Market Share in the Cell Based Immunotherapy Market
- Chimeric antigen receptor (CAR) T-cell therapy is a major advancement in cancer treatment. In this therapy, patient's own T cells are genetically engineered to express an artificial receptor that binds a tumor antigen. CAR-T cell therapy act against CD19 coded cancer antigens for the treatment of B cell cancers. Yescarta and Kymriah represent recently approved CAR T-cell therapy products indicated for the treatment of B cell malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, mantle cell lymphoma, chronic lymphoid leukemia and diffuse large B-Cell lymphoma.
- According to the International Agency for Research on Cancer (IARC), by the year 2040, it is estimated that new cases will cancer to grow to 27.5 million per year. In addition, the global cancer burden is anticipated to increase by 70% in the next 20 years.
- Chimeric Antigen Receptor (CAR) T-Cell Therapy segment holds a significant market share in the cell-based immunotherapy market and is anticipated to show a similar trend over the forecast period.
- Rising prevalence of cancer, technological advancement in developing target-based anti-cancer therapies and adoption of cell-based therapy is increased for the therapeutic purpose are the key driving factors in the chimeric antigen receptor (CAR) T-cell therapy segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global cell-based immunotherapy market due to the rising prevalence of cancer and the growing awareness of cell-based therapies in this region. According to the Disease Control and Prevention (CDC), nearly 245,000 cases of breast cancer in women and about 2,200 are diagnosed in men each year in the United States, approximately 41,000 women and 460 men in the United States die each year from breast cancer. Furthermore, ongoing research in cancer treatment, adoption of advanced technologies in cell-based therapies and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
The Cell Based Immunotherapy Market is consolidated competitive and consists of few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Novartis AG, Gilead Sciences, Inc (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co., Ltd and Green Cross Corp (GC Pharma).
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Rising Prevalence of Cancer
4.2.2 Technological Advancement in Developing Target Based Anti-cancer Therapies
4.2.3 Launches and Approval of Different Cell-based Immunotherapy Drugs
4.3 Market Restraints
4.3.1 High Cost of Technology
4.3.2 Lack of Awareness in the Developing Markets
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Autologous Cellular Immunotherapy
5.1.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy
5.1.3 Dendritic Cell-based Vaccine Therapy
5.2 By Primary Indication
5.2.1 B-cell Malignancies
5.2.2 Prostate Cancer
5.2.3 Renal Cell Carcinoma
5.2.4 Liver Cancer
5.3.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East and Africa
5.3.5 South America
18.104.22.168 Rest of South America
6.1.1 Novartis AG
6.1.2 Gilead Sciences, Inc (Kite Pharma)
6.1.3 Apac Biotech
6.1.4 Dendreon Pharmaceuticals LLC
6.1.5 JW CreaGene Co., Ltd
6.1.6 Green Cross Corp (GC Pharma)
A selection of companies mentioned in this report includes:
- Novartis AG
- Gilead Sciences, Inc (Kite Pharma)
- Apac Biotech
- Dendreon Pharmaceuticals LLC
- JW CreaGene Co., Ltd
- Green Cross Corp (GC Pharma)